<DOC>
	<DOC>NCT03020082</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of Ritonavir-boosted ASC08 (Danoprevir) in Combination with Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1.</brief_summary>
	<brief_title>Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>Willing and able to provide written informed consent Chronic HCV infection (≥ 6 months) Serum HCV RNA of ≥ 1 × 104 IU/mL are documented Hepatitis C virus GT1 Never received priortreatment for HCV with interferon, RBV, or other directacting or hosttargeting antivirals for HCV Noncirrhosis patients: Noncirrhosis is defined (1)Fibroscan defined as: ˂ 14.6 kPa during screening period, or liver biopsy determined 1 year before recruiting (Metavir score ˂ 3);(2) during screening period 9.6&lt;Fibroscan indicator ≤12.9, liver biopsy need to confirm noncirrhosis. Others as specified in the detailed protocol Patients with Fibroscan detection value &gt; 12.9 kPa, or histologic examination for liver cirrhosis patients Presence or history of nonhepatitis C chronic liver disease (e.g. HH, AIH, Wilson's disease, α1 antitrypsin deficiency, drug or toxininduced liver disease) History of liver cell cancer, or suspected hepatocellular carcinoma (HCC) patients before or during screening , or imaging studies found suspicious nodules, or AFP &gt; 50 ng/mL Positive hepatitis A antibody，positive hepatitis B surface antigen，HIV antibody Presence or history of nervous system diseases and/or mental illness, inability to control oneself or express oneself. Patients with obvious cardiovascular dysfunction Pregnant or nursing female, nor unwilling to take reliable contraception Others as specified in the detailed protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Danoprevir</keyword>
	<keyword>non-cirrhotic</keyword>
	<keyword>Chinese HCV G1</keyword>
	<keyword>SVR12</keyword>
</DOC>